Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced that it will report its second quarter 2019 financial results after the close of market on Thursday, August 8, 2019.
August 1, 2019
· 3 min read